Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mim8 prophylaxis in adults and adolescents with haemophilia A with or without inhibitors
2020-001048-24Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of treated bleeds. Started Nov 2020; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2020-001048-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001048-24.